PURPOSE:Short stature relative to the familial height potential is a universial characteristics of patients with Turner syndrome. growth hormone(GH)therapy has been shown to improve adult height in Turner syndrome. this study was done to determine the effects of GH treatment. Objects and METHOD:178 patients were enrolled by investigators at multiple center. Diagnosis of Turner syndrome confirmed by karyotype analysis. Growth rate of 121 patients who were given Recombinant human GH(0.6-1.0IU/kg/Week) by subcutaneous injection for 1-3 years were analized. Final adult height was defined by the growth rate which was less than 1cm/year. RESULTS:Height velocity increased significantly during GH treatment, particularly in the first year. mean height velocity of our Turner patients was 6.3(+/-.39)cm/year during the first year(121 patients), 5.3(+/-.72)cm/year during second year(92 patients), 4.6(+/-.62)cm/year during third year(72 patients) after GH treatment. Mean height velocity of our Turner patients without GH treatment was 3.8(+/-.47)cm/year. the final adult height of our Turner patients with GH trearment was 143.0(+/-.6)cm. the final adult height without GH trearment was 139.6(+/-.9)cm. CONCLUSION: Our data demonstrate that GH treatment seems effective in accelerating growth velocity and in improving final height in Turner syndrome. the final height of our Turner patients is not to be considered the best result, as most of them was received GH therapy late age.
Adult ; Diagnosis ; Female* ; Growth Hormone* ; Humans ; Injections, Subcutaneous ; Karyotype ; Research Personnel ; Turner Syndrome*

No abstract available.

No abstract available.
Chromatography, Liquid* ; Humans*

No abstract available.
Humans ; Turner Syndrome*

No abstract available.
Hyperplasia*

No abstract available.
Growth Hormone*

No abstract available.
Insulin-Like Growth Factor I ; Nutrition Assessment

recombinant human IGF-I in energy-restriction model. Experimental design; Sprague-Dawley rats(n=20) weighing 90-100g were used. Rats were fed a control diet two times a day(AM 8-11, PM 5-8) for four days after arrival and then assigned to one of three groups: control, energy-restricted, energy-restricted IGF-I treatment group. Energy restricted group was given with a decrese of 25% in the energy without changes in the protein by feeding 88% by weight to energy-restricted diet. During the 10days of energy restriction, the growth rate was reduced by 35%(2.70+-0.18g/day in energy restricted group vs. 4.13+-0.75g/day in the control group). At sacrifice, the tail lengh and weight of organs were not significantly decreased except the spleen and thymus(-17%: P<0.05). Serum IGF-I was reduced by 19% at the end of 10days of energy restriction. The glycemia, measured each day by glucometer from blood collected at the tail, was not reduced by energy restriction(105.4+-7.7 in control group vs. 101.3+-4.1mg/dl). The abundance of serum IGF-BPs was unchanged by this restriction.Despite the 1.5 fold increase of IGF-I concentration in energy restricted IGF-I injection group at sacrifice(1994+-172ng/ml vs. 1221+-110 ng/ml energy restricted group), IGF-I treatment(300 ug/day in twice sc injection for 6day) did not significantly accelerate the growth rate(body weight)(2.87+-0.20 vs. 2.70+-0.18g/day in energy restricted group).The glycemia was slightly reduced by IGF-I treatment(91.7+-5.0 mg/dl vs. 101.3+-4.5 mg/dl in energy restricted group), but it was not significant. However, the spleen and thymus weight, decreased by energy restriction, was completely normalized by IGF-I treatment.In summary, lack of a significant anabolic response to injection of IGF-I during energy restriction in this study may be associated with the compensatory growth response(alterations in dietary protein utilization) which followed initial period of energy restriction.
Animals ; Diet ; Dietary Proteins ; Humans ; Insulin ; Insulin-Like Growth Factor I ; Rats ; Rats, Sprague-Dawley ; Research Design ; Spleen ; Tail ; Thymus Gland

Testicular regression syndrome may be better known as vanishing testis syndrome to physicians. Such individuals are genetically male(46,XY), presenting with unilateral or bilateral absence of recognizable testis structures and absence of the Mullerian duct system. There is a wide spectrum of phenotypes depending on the stage of male embryogenesis at which testicular function ceased. We experienced a case of testicular regression syndrome presenting labial fusion at birth and report with the brief review of related literature.
Disorders of Sex Development ; Embryonic Development ; Female ; Humans ; Male ; Parturition ; Phenotype ; Pregnancy ; Testis

No abstract available.
Schizophrenia*